The McKinsey Quarterly, our business journal, includes many articles on healthcare-related topics.
Global pharma companies are missing a chance to serve Brazil’s increasingly prosperous and growing middle class.more
Lower profit margins suggest a need for new business models.more
A daunting array of financial and operational barriers is holding back growth. What can be done?more
The highest R&D costs are related to human resources. By following best practices, labs can attract the most talented employees and drive productivity.more
The PMP practice has published several compendia—compilations of insights on important trends and issues.
Highlights specific opportunities for operations to create significant value upside for pharmacos and emphasizes the role of the executive suite in enabling this value creation
Discusses how pharmaceutical companies will need to adjust their traditional sales models to suit the evolving healthcare landscape (PDF–5.9 MB)more
Recent years have seen a collapse in the industry’s R&D productivity. Regaining trust by delivering life-changing new drugs is still an achievable goal, but it will require discipline, creativity, and luck in equal measure. Part of the 2012 R&D compendium.
Reviews our major recommendations for improving pharmaceutical operations and increasing client capabilities.
Provides insights on achieving excellence in all stages of the commercial process.Versions are available for the US and EU markets
Our white papers examine a single issue in depth, providing clients with a rigorous fact base, objective perspectives, and new insights into pressing industry issues.
Clinical pathways will have a long term effect on the practice of oncology. Pharmaceutical companies can realize value if they understand how pathway solutions are developed and use these insights as an input to their own R&D and commercialization strategies. (PDF–444 KB)more
Real-world data, collected at the point of care, is beginning to create new opportunities throughout the healthcare business system. (PDF–470 KB)more
As price pressures increase, medical device makers can use Design to Value to control costs and deliver value. (PDF–671 KB)more
The US government recently updated legislation related to biosimilars. Payors, originators, and biosimilar companies must be aware of its implications, as well as areas that remain ambiguous. (PDF–130 KB)more
Multinational corporations have traditionally had little success when entering in-bound alliances with Japanese pharmaceutical companies. But new circumstances make it the ideal time to pursue such deals. (PDF–743 KB)more
New reimbursement guidelines make it difficult for pharmaceutical companies to earn profits on recently approved products. A cross-functional strategy, involving both R&D and commercial functions, can help them maximize value. (PDF–293 KB)more
By developing robust clinical strategies early in a drug's lifecycle, pharmaceutical companies can generate data that will build the clinical profile of the brand over its lifetime. (PDF–87.5 KB)more
By drawing on examples from other industries, pharmaceutical companies can take an entrepreneurial approach that helps key account managers create innovative solutions. (PDF–497 KB)more
The Indian pharmaceutical market is growing rapidly. Businesses that are aware of trends and the changing nature of opportunities will be well positioned to capture value. (PDF–1.43 MB)more
The Care Pathway uses customer insights to create a comprehensive, strategic view of disease areas, and identify the key moments when pharmaceutical companies can help patients obtain the best care. (PDF–1.06 MB)more
The pharmaceutical industry is no longer recession-proof. To survive, companies must not only reduce costs but seize opportunities to explore new business models, become more flexible, and build capabilities. (PDF–226 KB)more
We publish selected articles in industry magazines including In Vivo, The RPM Report, Nature Reviews Drug Discovery, Pharmaceutical Manufacturing, Pharmaceutical Executive, PharmaVoice, and others.
This article describes why various healthcare stakeholders are using social media and provides a perspective on how pharmaceutical companies can make the most of it. (PDF–193 KB)more
Providers, payors, and regulators are placing new emphasis on comparative efficacy when evaluating medical devices. To succeed in the new environment, companies will need to focus on products that have value over existing therapies. (PDF–123 KB)more